AnaptysBio Financial Ratios
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
45.95-0.26 (-0.56%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio ratio analysis
AnaptysBio earned a net margin of -5.6% in FY 2025, up from -159.1% a year earlier. Return on equity reached -35.6%, meaning AnaptysBio generated -0.36 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 3.67 | 3.03 | 22.41 | 56.57 | 10.06 | 5.22 | 34.05 | 215.15 | 132.83 | — |
| Price / book | 23.16 | 3.90 | 4.36 | 2.22 | 1.78 | 0.99 | 0.67 | 2.21 | 4.32 | — |
| Operating margin | 96.7% | 72.5% | -958.3% | -1,119.4% | -89.9% | -31.8% | -1,342.9% | -1,334.4% | -287.8% | -18.1% |
| Net margin | -5.6% | -159.1% | -953.7% | -1,251.3% | -91.5% | -26.6% | -1,216.7% | -1,233.1% | -300.7% | -25.5% |
| Free cash flow margin | 8.4% | -148.7% | -708.8% | -718.9% | -74.8% | -19.6% | -879.0% | -991.4% | -197.3% | -54.4% |
| Return on equity (ROE) | -35.6% | -204.9% | -185.7% | -49.1% | -16.2% | -5.0% | -24.0% | -12.7% | -9.8% | — |
| Return on assets (ROA) | -3.6% | -30.0% | -36.2% | -21.1% | -9.0% | -4.8% | -22.4% | -12.1% | -9.1% | -6.8% |
| Current ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
| Revenue growth | 157.0% | 432.0% | 66.8% | -83.7% | -15.8% | 837.5% | 60.0% | -50.0% | -40.1% | -5.0% |